With CMTA support of $300,000, CMTA Strategy To Accelerate Research (CMTA-STAR) Advisory Board member Bruce...
Tiny Movers, Big Clues: Dr. Manor Uses AI to Shed Light on CMT2A
CMTA-funded CMT2A treatment research at UC San Diego is building the tools to develop ASO therapies targeting the faulty MFN2 gene, with a clear path toward treatments.
CMT2A Biomarkers and Natural History
With CMTA support of $572,055, researchers at the Inherited Neuropathy Consortium led by Michael E. Shy, MD, are working to track disease progression and identify biomarkers in CMT2A. By studying blood, skin biopsy, and MRI biomarkers alongside clinical assessments, this project aims to develop critical tools for future clinical trials and advance CMT2A research.
2A Biomarkers and Outcome Measures
With CMTA support of $572,055, an international team of researchers from the Inherited Neuropathy Consortium,...
